Clinical Trial

Genetically Modified T Cells Against Ovarian Cancer

Name: Genetically Modified T Cells Against Ovarian Cancer — clinical trial record (NCT03184753)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2017-06-10; most recent amendment 2025-09-04.

Trial Details

NCT Number	NCT03184753
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Ovarian Cancer
Enrollment	100 participants
Start Date	2025-05-01
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-08